Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACUR Acura Pharmaceuticals	$0.00	$0.00	$0.00 ▼ $0.05	$186K	1.89	3,228 shs	4,050 shs
EARS Auris Medical	$1.50 +1.4%	$2.88	$0.73 ▼ $6.60	$17.13M	1.17	3.10 million shs	23,428 shs
ICOTF iCo Therapeutics	$0.39	$0.37	$0.80 ▼ $1.82	$3.53M	2.03	4,760 shs	1,000 shs
XBIO Xenetic Biosciences	$4.00 +3.6%	$4.07	$2.55 ▼ $5.97	$6.16M	2.6	6,022 shs	7,896 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACUR Acura Pharmaceuticals	0.00%	0.00%	-33.33%	+154.55%	-94.40%
EARS Auris Medical	-9.20%	-26.00%	-12.43%	-38.33%	+24.37%
ICOTF iCo Therapeutics	-0.46%	-9.76%	-6.49%	-8.14%	-0.46%
XBIO Xenetic Biosciences	-3.86%	-17.63%	-9.18%	+12.87%	-16.99%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACUR Acura Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EARS Auris Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACUR Acura Pharmaceuticals	N/A	N/A	N/A	N/A
EARS Auris Medical	N/A	N/A	N/A	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	2.00	Hold	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACUR Acura Pharmaceuticals	$1.56M	0.12	N/A	N/A	N/A	∞
EARS Auris Medical	N/A	N/A	N/A	N/A	$1.57 per share	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A
XBIO Xenetic Biosciences	$2.54M	2.43	N/A	N/A	$6.36 per share	0.63

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACUR Acura Pharmaceuticals	-$880K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EARS Auris Medical	-$8.75M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ICOTF iCo Therapeutics	-$1.11M	-$0.40	N/A	∞	N/A	N/A	N/A	-288.85%	N/A
XBIO Xenetic Biosciences	-$4.14M	-$2.75	N/A	N/A	N/A	-162.84%	-36.43%	-33.74%	5/9/2024 (Estimated)

Latest EARS, ICOTF, XBIO, and ACUR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	XBIO Xenetic Biosciences	-$0.87	-$0.77	+$0.10	-$0.77	$0.68 million	$0.67 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACUR Acura Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EARS Auris Medical	N/A	N/A	N/A	N/A	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACUR Acura Pharmaceuticals	N/A	N/A	N/A
EARS Auris Medical	N/A	3.83	3.83
ICOTF iCo Therapeutics	N/A	0.72	0.72
XBIO Xenetic Biosciences	N/A	11.84	11.84

Ownership

Institutional Ownership

Company	Institutional Ownership
ACUR Acura Pharmaceuticals	N/A
EARS Auris Medical	6.03%
ICOTF iCo Therapeutics	N/A
XBIO Xenetic Biosciences	15.12%

Insider Ownership

Company	Insider Ownership
ACUR Acura Pharmaceuticals	20.20%
EARS Auris Medical	N/A
ICOTF iCo Therapeutics	N/A
XBIO Xenetic Biosciences	9.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACUR Acura Pharmaceuticals	9	66.35 million	52.95 million	Not Optionable
EARS Auris Medical	132,200	11.42 million	N/A	Not Optionable
ICOTF iCo Therapeutics	N/A	9.05 million	N/A	Not Optionable
XBIO Xenetic Biosciences	4	1.54 million	1.40 million	Not Optionable

EARS, ICOTF, XBIO, and ACUR Headlines

Source	Headline
	Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Drop in Short Interest americanbankingnews.com - April 13 at 3:22 AM
	Xenetic Biosciences Inc (XBIO) investing.com - April 10 at 3:28 PM
	Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - March 24 at 5:09 PM
	Xenetic Dips on Full-Year Results baystreet.ca - March 22 at 7:33 PM
	Xenetic Biosciences reports FY results msn.com - March 22 at 8:51 AM
	Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results accesswire.com - March 22 at 8:00 AM
	Xenetic to advance DNase programme with UVA partnership msn.com - January 18 at 1:37 PM
	Xenetic Biosciences Inc XBIO morningstar.com - January 4 at 5:10 PM
	Xenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecast benzinga.com - December 11 at 9:01 AM
	Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation finance.yahoo.com - November 30 at 10:39 AM
	Xenetic Biosciences: Q3 Earnings Insights benzinga.com - November 10 at 3:38 PM
	MediciNova: Q3 Earnings Snapshot washingtonpost.com - November 10 at 10:37 AM
	Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference finance.yahoo.com - October 11 at 9:30 AM
	Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock? msn.com - July 13 at 1:44 PM
	Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - May 11 at 5:06 PM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison \| Morningstar morningstar.com - May 5 at 10:21 AM
	Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development finance.yahoo.com - May 4 at 10:02 AM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison finance.yahoo.com - May 3 at 10:26 AM
	HC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendation msn.com - April 12 at 10:37 PM
	Xenetic Biosciences forms research collaboration with TSRI pharmaceutical-technology.com - April 12 at 12:36 PM
	Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO) markets.businessinsider.com - April 12 at 2:30 AM
	Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform finance.yahoo.com - April 11 at 8:43 AM
	JTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finanznachrichten.de - March 16 at 12:09 PM
	JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finance.yahoo.com - March 16 at 12:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

5 Undervalued AI Stocks and Why to Buy Them
March 20, 2024 7:41 AM
View 5 Undervalued AI Stocks and Why to Buy Them
PayPal Appears to Have Bottomed, is it Time to Buy?
March 22, 2024 9:11 AM
View PayPal Appears to Have Bottomed, is it Time to Buy?
3 High Short Interest Stocks Ready to Squeeze
April 9, 2024 7:04 AM
View 3 High Short Interest Stocks Ready to Squeeze
Headwinds for Darden Restaurants are an Opportunity For Investors
March 22, 2024 9:20 AM
View Headwinds for Darden Restaurants are an Opportunity For Investors
Dave & Buster’s Stock Value Is Unleashed, Not Too Late To Get In
April 3, 2024 8:55 AM
View Dave & Buster’s Stock Value Is Unleashed, Not Too Late To Get In

All Headlines

Company Descriptions

Acura Pharmaceuticals

OTCMKTS:ACUR

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

Auris Medical

NASDAQ:EARS

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

iCo Therapeutics

OTCMKTS:ICOTF

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Xenetic Biosciences

NASDAQ:XBIO

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial